PD-0009 Primary Tumor Location is a Major Independent Prognostic Factor for Mcrc Patients

摘要: ABSTRACT Introduction Previous attempts to address the question of whether primary tumor location affects outcome mCRC were limited by small sample size, a high degree heterogeneity in received treatments, and/or information regarding molecular and pathologic features. We performed present analysis clarify prognostic impact patients (pts). Methods Cancers proximal or distal splenic flexure classified as right- left-sided respectively. Firstly, we tested association with cohort 200 pts treated FOLFIRI plus bevacizumab within prospective 1st-line pharmacogenetic study. For these data on mucinous histology BRAF mutational status available. Secondly, from two large randomized phase III trials (AVF2107 NO16966) first-line chemotherapy minus used for validation. Primary endpoint was OS. Results In initial 56 (28.0%) 144 (72.0%) right-sided Right-sided cancers had worse both terms PFS OS (PFS, left vs right: HR = 0.43[95%CI: 0.28-0.66], p = 0.0001; OS: HR = 0.37[95%CI:0.22-0.63], p = 0.0003). A multivariate model confirmed an adverse variable independent status. subgroup non-mucinous wild-type tumors (N = 155), achieved median 10.0 28.9 months compared 13.0 47.6 mos HR = 0.54[95%CI:0.34-0.84], p = 0.003; HR = 0.52[95%CI:0.30-0.93], p = 0.022). AVF2107 study, available 559 (68.8%). Of these, 353 (63.2%) 206 (36.8%) right-sided. Left-sided better (median 20.4 14.6 months, HR = 0.55[95%CI: 0.43-0.70], p  Conclusion These suggest strong mCRCs’ outcome. Tumor did not effect bevacizumab. Recent mRNA signatures different background CRC. Given consistency across exploratory set confirmatory studies, side origin should be considered stratification factor future clinical mCRC. Table 1 .